PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.02
Positive D/E while AGEN shows negative equity. John Neff would examine our competitive advantages in a challenging market.
3.80
Dangerously higher net debt above 1.5x AGEN's 0.59. Jim Chanos would check for potential debt spiral risks.
-2327.49
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
1.50
Current ratio 50-75% of AGEN's 2.01. Bill Ackman would demand clear path to liquidity improvement.
No Data
No Data available this quarter, please select a different quarter.